Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anakinra - Swedish Orphan Biovitrum

Drug Profile

Anakinra - Swedish Orphan Biovitrum

Alternative Names: Antril; Kineret; Recombinant human interleukin-1 receptor antagonist; rhIL-1ra

Latest Information Update: 19 Oct 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; CHRU de Tours; Swedish Orphan Biovitrum
  • Class Anti-inflammatories; Antigouts; Antirheumatics; Recombinant proteins
  • Mechanism of Action Immunomodulators; Interleukin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cryopyrin-associated periodic syndromes; Juvenile rheumatoid arthritis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cryopyrin-associated periodic syndromes; Rheumatoid arthritis
  • Registered Adult-onset Still's disease; Juvenile rheumatoid arthritis
  • Phase III COVID 2019 infections
  • Phase II Autoimmune disorders; Gout; Non-Hodgkin's lymphoma
  • Discontinued Ankylosing spondylitis; Graft-versus-host disease; Osteoarthritis; Pneumococcal infections; Septic shock

Most Recent Events

  • 05 Oct 2020 Phase-II clinical trials in Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in USA (SC) (NCT04150913)
  • 03 Jun 2020 Efficacy and immunogenicity data from a phase II anaGO trial in Gout presented at the 21st Annual Congress of the European League Against Rheumatism (EULAR-2020)
  • 27 Apr 2020 Phase-III clinical trials in COVID-2019 infections (Combination therapy) in France (IV) (EudraCT2020-001734-36)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top